Janney Montgomery Scott LLC Boosts Stake in Haleon PLC Sponsored ADR (NYSE:HLN)

Janney Montgomery Scott LLC lifted its position in Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) by 4.6% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 889,394 shares of the company's stock after purchasing an additional 38,831 shares during the period. Janney Montgomery Scott LLC's holdings in Haleon were worth $9,152,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Wellington Management Group LLP grew its position in shares of Haleon by 67.5% during the 4th quarter. Wellington Management Group LLP now owns 15,328,325 shares of the company's stock worth $146,232,000 after buying an additional 6,175,835 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in Haleon in the fourth quarter worth about $45,110,000. Raymond James Financial Inc. purchased a new stake in Haleon in the fourth quarter worth about $42,193,000. FMR LLC grew its holdings in Haleon by 3.7% during the 4th quarter. FMR LLC now owns 108,827,814 shares of the company's stock worth $1,038,217,000 after acquiring an additional 3,909,545 shares in the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich purchased a new position in Haleon during the 4th quarter valued at about $39,628,000. Institutional investors own 6.67% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on HLN. Hsbc Global Res cut shares of Haleon from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. Wall Street Zen upgraded Haleon from a "hold" rating to a "buy" rating in a report on Friday, June 6th. BNP Paribas raised Haleon to a "strong-buy" rating in a research report on Tuesday, May 27th. Barclays reissued an "overweight" rating on shares of Haleon in a research report on Tuesday, May 6th. Finally, Morgan Stanley raised Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price objective on the stock in a research report on Friday, May 9th. Five investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $12.33.

Haleon Stock Up 0.0%

HLN stock traded up $0.01 on Tuesday, hitting $10.50. 14,925,274 shares of the company's stock were exchanged, compared to its average volume of 9,158,512. The firm has a 50 day moving average price of $10.70 and a two-hundred day moving average price of $10.11. Haleon PLC Sponsored ADR has a 12-month low of $8.25 and a 12-month high of $11.42. The stock has a market cap of $47.19 billion, a P/E ratio of 26.91, a price-to-earnings-growth ratio of 2.96 and a beta of 0.31. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.78 and a current ratio of 0.98.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.